TrialTransplantation and cellular therapy2023

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Alexander E Perl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.